Preclinical Biomarker Articles & Analysis
3 news found
Cellworks Group Inc., a leader in Personalized Therapy Biosimulation, today announced the launch of its Precision Drug Development business units aimed at accelerating time-to-market for drug development and reviving previously studied but unapproved pharmaceutical assets through predictive biosimulation. The two new business units will use Cellworks’ biosimulation platform and ...
LONDON, June 27, 2022– Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, today announced that the first patient has been dosed in the OBERTO 301 Phase 2 trial of PolyPEPI1018, the Company’s lead product candidate, in combination with atezolizumab, ...
LONDON, February 7, 2022– Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, today announced that the first patient has been dosed in the OBERTO 201 Phase 1b trial of PolyPEPI1018, the Company’s lead product candidate, as an add-on to ...